ARCHIVES

Phase III Trial Would Give Clearer Picture Of C225 Role.

This article is from The Cancer Letter archive.

Vol. 28 No. 07 | February 15, 2002

Download PDF Visit The Full Archive

Related Articles

Prognostic Factors Don’t Explain Better Prostate Cancer Survival In Most Asian Men

August 31, 2007

Low Prevalence Of Tamoxifen Use For Cancer Prevention

February 26, 2010

House Panel Recommends $642 Million Increase For NIH; $31 Million Increase For NCI

July 21, 1995

CCOP Reponses So Far Indicates application To Total 150-200

August 27, 1982

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

June 30, 2006

More Than 3,000 Letters If Intent Sent To army For Breast Programs

September 10, 1993